Sec. 411. Meaningful access to Federal health plan claims data
1,815 words·~8 min read·
/bill/117/hr/6000/ih/section-411·A research copy — for the controlling text, always check the official state or federal source. Not legal advice.
Congress finds as follows: Clinician-led clinical data registries serve an important role in promoting, facilitating, and conducting medical research and improving quality of healthcare by providing timely and actionable feedback to practitioners on their performance in relation to other practitioners and best clinical practices. Clinician-led clinical data registries are hindered in their ability to promote medical research and quality improvement by their lack of meaningful access to claims data.
While the Centers for Medicare & Medicaid Services has established programs for providing access to claims data, those programs fail to provide clinician-led clinical data registries with meaningful access to such data. Ensuring clinician-led clinical data registries meaningful access to claims data will enable such entities to better track patient outcomes over time, expand their ability to assess the safety and effectiveness of medical treatments, and provide them with the information necessary to assess the cost-effectiveness of therapies.
The Secretary shall establish a new program (separate from any existing data access programs, including, without limitation, the Centers for Medicare & Medicaid Services Qualified Entity (in this section, referred to as QE ) Program ( 42 U.S.C. 1395kk(e) , 1395kk–2) (in this section, referred to as the Medicare Data Sharing for Performance Measurement Program ) and the Research Data Assistance Center (in this section, referred to as the ResDAC ) process) under which the Secretary shall, at the request of a clinician-led clinical data registry, provide timely, broad, and continuous access to a database of claims data to such clinician-led clinical data registry for purposes of research, quality of care measurement and reporting to health care providers, linking such data with clinical data and performing risk-adjusted, scientifically valid analyses and research to support quality improvement or patient safety, and other purposes and uses described herein or approved by the Secretary.
Access to a database of claims data pursuant to this subsection shall not be more restrictive than access to data provided under the QE Program or the ResDAC process. Prior to gaining access to a database of claims data under the program established in subsection (a), a clinician-led clinical data registry shall submit to the Secretary an application demonstrating that it is qualified (as determined by the Secretary) to use claims data. Upon the Secretary’s approval of a clinician-led clinical data registry’s application described in this subparagraph, the Secretary shall provide access to a database of claims data to such clinician-led clinical data registry for a period of at least 5 years.
After the expiration of the time period described in this subparagraph, the clinician-led clinical data registry shall reapply to access the database of claims data under the program established in subsection (a). The Secretary shall establish a streamlined initial application and recertification application process under which the Secretary shall approve or deny the clinician-led clinical data registry’s application described in subparagraph (2)(A) within 60 calendar days after receiving the application unless the Secretary demonstrates a compelling reason for needing additional time to complete the process.
If the clinician-led clinical data registry’s application described in subparagraph (2)(A) is denied, the Secretary shall provide the reason(s) for denial. The Secretary shall develop and maintain a process by which a clinician-led clinical data registry may appeal— the Secretary’s decision to deny an application described in paragraph (2); and the Secretary’s failure to approve or deny the clinician-led clinical data registry’s application described in paragraph
(2)within a reasonable time frame established by the Secretary. The Secretary shall render a decision with respect to an appeal filed by a clinician-led clinical data registry pursuant to subparagraph
(A)in a timely manner, not to exceed 60 calendar days after the Secretary receives the clinician-led clinical data registry’s request for an appeal. Notice of such decision shall be provided to the clinician-led clinical data registry filing the appeal before the conclusion of such 60-day period. The Secretary shall structure its database of claims data to allow for various data set queries, including, but not limited to, provider-specific claims data, clinical specialty-specific claims data, state-specific claims data, and nationwide claims data. The Secretary shall promptly make available to a clinician-led clinical data registry access to claims data requested by such clinician-led clinical data registry within a reasonable timeframe, not to exceed 30 calendar days, after the Secretary approves the request from the clinician-led clinical data registry. Clinician-led clinical data registries may— make available to the public reports evaluating the performance of providers of services and suppliers using the claims data provided to such clinician-led clinical data registry under subsection
(a)in combination with registry data; use claims data received under subsection
(a)combined with registry data to conduct additional nonpublic analyses and provide or charge an access fee for such analyses to authorized users for nonpublic use; provide or charge an access fee for data sets that link claims data received under subsection
(a)with registry data to authorized users for nonpublic use; and provide or charge an access fee for claims data received under subsection
(a)to authorized users for nonpublic use. Claims data shall be provided to a clinician-led clinical data registry under subsection
(a)at a reasonable fee based on the cost of providing such data to the clinician-led clinical data registry. Such fee shall be based at least in part on the number of patients included in the claims data provided to such clinician-led clinical data registry. Any fee collected pursuant to the preceding sentences shall be deposited in the Centers for Medicare & Medicaid Services Program Management Account. A clinician-led clinical data registry may charge a reasonable, cost-based fee for providing to authorized users claims data, data sets linking claims data with registry data, or analyses described in subsection (b). The Secretary shall provide access to a database of claims data pursuant to subsection
(a)in accordance with applicable information, privacy, security, and disclosure laws, including, without limitation, the Health Insurance Portability and Accountability Act of 1996 ( Public Law 104–191 ) as amended by the privacy and security provisions set forth in section 13400 of the Health Information Technology for Economic and Clinical Health Act ( Public Law 111–5 ), the regulations promulgated thereunder codified at parts 160 and 164 of title 45, Code of Federal Regulations, and subparagraphs
(A)through
(B)of section 105(a)(3) of the Medicare Access and CHIP Reauthorization Act of 2015 ( 42 U.S.C. 1395kk–2(a)(3) ). An authorized user shall not use analyses or data provided or sold under paragraphs
(2)through
(4)of subsection
(b)for marketing purposes. An authorized user in receipt of an analysis or datum provided or sold under paragraphs
(2)through
(4)of subsection
(b)shall comply with section 105(a)(5) of Medicare Access and CHIP Reauthorization Act of 2015 ( 42 U.S.C. 1395kk–2(a)(5) ). Prior to a clinician-led clinical data registry using, providing, or charging an access fee for claims data, data sets linking claims data with registry data, or analyses described in subsection (b), to the extent that such data, data sets, or analyses would individually identify a provider of services or supplier who is not being provided or sold such data, data sets, or analyses, such clinician-led clinical data registry shall confidentially make available such data, data sets, or analyses to such provider of services or supplier and provide such provider of services or supplier with the opportunity to appeal and correct errors. A clinician-led clinical data registry and an authorized user shall enter into a data use agreement regarding the use or disclosure of any claims data or data sets that link claims data with registry data that the clinician-led clinical data registry is providing or charging an access fee to the authorized user under paragraphs
(3)through
(4)of subsection (b). Such agreement shall include the requirements and prohibitions described in section 105(a)(4) of the Medicare Access and CHIP Reauthorization Act of 2015 ( 42 U.S.C. 1395kk–2(a)(4) ). In the case of a breach of a data use agreement described in subsection (e), the Secretary shall impose an assessment on the clinician-led clinical data registry and the authorized user. The assessment under paragraph
(1)shall be in an amount up to $100 for each individual entitled to, or enrolled for, benefits under part A of title XVIII of the Social Security Act or enrolled for benefits under part B of such title for whom the clinician-led clinical data registry provided data on to the authorized user. Any amounts collected pursuant to this subsection shall be deposited in the Federal Supplementary Medical Insurance Trust Fund under section 1841 of the Social Security Act ( 42 U.S.C. 1395t ). Claims data released to a clinician-led clinical data registry under subsection
(a)shall not be subject to discovery or admission as evidence in judicial or administrative proceedings without consent of the applicable provider of services or supplier. Not later than 2 years after the date of the enactment of this Act, and annually thereafter, the Secretary shall submit to Congress a report on the extent to which clinician-led clinical data registries are afforded meaningful access to claims data. In this subtitle: The term authorized user has the meaning given such term in section 105(a)(9)(A) of the Medicare Access and CHIP Reauthorization Act of 2015 ( 42 U.S.C. 1395kk–2(a)(9)(A) ), as well as a government agency or other governmental entity, researchers, entities that seek data for purposes of complying with regulations or other requirements of the Federal Food and Drug Administration, and other entities approved by the Secretary. The term claims data has the meaning given to the term data in section 105(b)(1)(B) of the Medicare Access and CHIP Reauthorization Act of 2015 ( 42 U.S.C. 1395kk–2(b)(1)(B) ). The term clinician-led clinical data registry has the meaning given such term in section 4005(b) of the 21st Century Cures Act. The term nonpublic use means a use for the purpose of— promoting, facilitating, and conducting medical research, assisting providers of services and suppliers to improve patient safety, and to develop and participate in quality and patient care improvement activities, including developing new models of care; assisting clinician-led clinical data registries in developing and reporting quality measures to health care providers quality measures; educating a government agency or other governmental entity; and supporting clinical trials and other activities necessary to comply with pre- or post-market approval or adverse event reporting requirements or conditions imposed by the Food and Drug Administration, and other purpose approved by the Secretary. The term provider of services has the meaning given such term in section 1861(u) of the Social Security Act ( 42 U.S.C. 1395x(u) ). The term supplier has the meaning given such term in section 1861(d) of the Social Security Act ( 42 U.S.C. 1395x(d) ). Not later than 1 year after the date of the enactment of this Act, the Secretary of Health and Human Services shall promulgate final regulations to implement the provisions of the preceding sections of this subtitle.
Connectionstraces to 3
Traces to 3 documents
7 references not yet in our index
- Pub. L. 104-191
- Pub. L. 111-5
- 42 USC 1395kk–2(a)(3)
- 42 USC 1395kk–2(a)(5)
- 42 USC 1395kk–2(a)(4)
- 42 USC 1395kk–2(a)(9)(A)
- 42 USC 1395kk–2(b)(1)(B)
Citation graph
cites case law
Sec. 411
Meaningful access to Federal health plan claims data
Pub. L.Pub. L. 104-191
Pub. L.Pub. L. 111-5
Cite42 USC 1395kk–2(a)(3)
Cite42 USC 1395kk–2(a)(5)
Cite42 USC 1395kk–2(a)(4)
Cites 10 · showing 8Cited by 0 across 0 sources